Perfromance Wealth Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Perfromance Wealth Partners’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-16,500	Closed	-$81.2K	–	184
2024 Q1	$81.2K	Buy	+16,500	New	+$97.7K	﹤0.01%	164
2023 Q4	–	Sell	-18,500	Closed	-$212K	–	179
2023 Q3	$212K	Hold	18,500	–	–	0.01%	158
2023 Q2	$457K	Buy	18,500 +3,000	+19%	+$93.5K	0.02%	123
2023 Q1	$499K	Buy	15,500 +2,500	+19%	+$77.9K	0.03%	112
2022 Q4	$240K	Hold	13,000	–	–	0.01%	145
2022 Q3	$351K	Hold	13,000	–	–	0.02%	116
2022 Q2	$180K	Hold	13,000	–	–	0.01%	163
2022 Q1	$254K	Hold	13,000	–	–	0.01%	149
2021 Q4	$212K	Buy	+13,000	New	+$217K	0.01%	172

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Perfromance Wealth Partners's RVNC Position: Q2 2024 in Review

Perfromance Wealth Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 16,500 shares — an estimated $81.2K sold.

Perfromance Wealth Partners first reported a position in RVNC in Q4 2021 and held it in 9 quarters. The position peaked at $499K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

Perfromance Wealth Partners reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
Perfromance Wealth Partners sold 16,500 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $81.2K.
Perfromance Wealth Partners first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 9 quarters.
Perfromance Wealth Partners's Revance Therapeutics, Inc. position peaked at $499K in Q1 2023.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Perfromance Wealth Partners's 13F filing for Q2 2024, filed 22 Jul 2024.